GlassScriptPhysician profile
Denyse Gallagher
NPI 1588075055
$9,556.63
in general payments reported to CMS, 2019-2025
37 companies · $1,781 in 2025
The $1,781 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $3,455 · 2023: $1,472 · 2024: $2,143 · 2025: $1,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,336 · Gift: $59.40 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,335.69 |
| Gift | $59.40 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,523.62 | 2022-2025 | Minimed 780g, Minimed 770g |
| Abbott Laboratories | $1,636.16 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $1,157.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $578.86 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $443.02 | 2021-2025 | |
| Dexcom, INC. | $435.02 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $429.27 | 2023-2025 | Omnipod |
| Cequr Corporation | $286.29 | 2023-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.75 | 2021-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $211.09 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $130.63 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $123.28 | 2021-2025 | Korlym |
| Madrigal Pharmaceuticals | $116.17 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $111.29 | 2022-2025 | Tirosint, Licart, Flector |
| Bayer Healthcare Pharmaceuticals INC. | $102.86 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $102.86 | 2021-2023 | Afrezza |
| Tolmar, INC. | $99.99 | 2024-2025 | Jatenzo |
| Amgen INC. | $89.19 | 2024-2025 | Evenity, Tepezza |
| Beta Bionics, INC. | $83.07 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $70.31 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $65.96 | 2022-2025 | Unithroid |
| Edwards Lifesciences Corporation | $56.61 | 2025 | |
| Embecta Corp. | $53.81 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Alexion Pharmaceuticals, INC. | $49.50 | 2021-2025 | Strensiq |
| Antares Pharma, INC. | $48.96 | 2022-2025 | Xyosted |
| Currax Pharmaceuticals LLC | $41.85 | 2021-2023 | Contrave |
| Novartis Pharmaceuticals Corporation | $32.19 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $30.98 | 2021-2022 | |
| Becton, Dickinson and Company | $27.87 | 2022 | |
| Alfasigma USA, INC. | $26.00 | 2022 | |
| Halozyme INC | $21.73 | 2023 | |
| Averitas Pharma INC. | $17.98 | 2025 | Qutenza |
| Sequel Med Tech, LLC | $17.18 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $16.39 | 2023 | |
| Ascendis Pharma Endocrinology INC | $15.77 | 2023 | |
| Radius Health, INC. | $13.92 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denyse Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.